This product is a selective α1 receptor blocker that can reduce peripheral vascular resistance and has a hypotensive effect on both systolic and diastolic blood pressure. It is usually not accompanied by tachycardia, has no adverse effects on electrolytes, blood sugar, liver and kidney function, and has a certain improvement effect on blood lipids. This product also has the effect of relaxing bladder and prostate smooth muscles, and can relieve symptoms such as dysuria caused by benign prostatic hypertrophy.

This drug is a chemically semi-synthetic clindamycin derivative. It is rapidly hydrolyzed into clindamycin after entering the body and shows its pharmacological activity. The antibacterial spectrum, antibacterial activity and therapeutic effect are the same as those of clindamycin, but its fat solubility and permeability are better than those of clindamycin. It can be taken orally, intramuscularly or intravenously. Compared with lincomycin, it has a 4-8 times stronger antibacterial effect, good absorption, high bone concentration, and good efficacy against anaerobic infections. It has strong antibacterial activity mainly against Gram-positive cocci and anaerobic bacteria, including Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus (except carbonyl streptococcus), Streptococcus pneumoniae, Micrococcus, as well as Clostridium, Bacteroides, Clostridium, Propionibacterium, Eubacterium, Necrococcus, etc.

Extract from the above information

Extract from the above information